Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | BTK |
| Variant | C481T |
| Impact List | missense |
| Protein Effect | no effect |
| Gene Variant Descriptions | BTK C481T lies within the protein kinase domain of the Btk protein (UniProt.org). C481T demonstrates kinase activity similar to wild-type Btk, but confers Imbruvica (ibrutinib) resistance in cell culture (PMID: 27282255). |
| Associated Drug Resistance | Y |
| Category Variants Paths |
BTK mutant BTK C481X BTK C481T |
| Transcript | NM_000061.3 |
| gDNA | chrX:g.101356176_101356177delTGinsAC |
| cDNA | c.1441_1442delTGinsAC |
| Protein | p.C481T |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_000061.3 | chrX:g.101356176_101356177delTGinsAC | c.1441_1442delTGinsAC | p.C481T | RefSeq | GRCh38/hg38 |
| NM_000061 | chrX:g.101356176_101356177delCAinsGT | c.1441_1442delTGinsAC | p.C481T | RefSeq | GRCh38/hg38 |
| NM_000061.2 | chrX:g.101356176_101356177delTGinsAC | c.1441_1442delTGinsAC | p.C481T | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK C481X | chronic lymphocytic leukemia | predicted - resistant | Ibrutinib | Phase II | Actionable | In a Phase II trial, BTK C481X and/or PLCG2 mutations were identified in 80% (8/10) of patients with progressive disease and in 20% (1/5) of patients with prolymphocytic transformation of chronic lymphocytic leukemia while on Imbruvica (ibrutinib) treatment (PMID: 28049639, NCT01500733). | 28049639 |